Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial) - 28/08/11
Doi : 10.1016/j.amjcard.2003.06.006
Dale T. Ashby, MBBS, PhD a, Eve A. Aymong, MD a, Cindy L. Grines, MD b, David A. Cox, MD c, Eulogio Garcia, MD d, Roxana Mehran, MD a, James E. Tcheng, MD e, John J. Griffin, MD f, Giulio Guagliumi, MD g, Thomas Stuckey, MD h, John D. Carroll, MD i, Mark Turco, MD j, Alexandra J. Lansky, MD a, Gregg W. Stone, MD a, ⁎ 
a Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New York City, New York, USA
b William Beaumont Hospital, Royal Oak, Michigan, USA
c Mid Carolina Cardiology, Charlotte, North Carolina, USA
d Hospital Gregorio Maranon, Madrid, Spain
e Duke Clinical Research Institute, Durham, North Carolina, USA
f Virginia Beach General Hospital, Virginia Beach, Virginia, USA
g Ospedali Riuniti di Bergamo, Bergamo, Italy
h Moses Cone Memorial Hospital, Greensboro, North Carolina, USA
i University of Colorado Health Sciences Center, Denver, Colorado, USA
j Washington Adventist Hospital, Tacoma Park, Maryland, USA
*Dr. Stone's address is: Cardiovascular Research Foundation, 55 East 59th Street, 6th Floor, New York, New York, 10022, USA.
Abstract |
The results of bail-out stenting after unsuccessful primary balloon angioplasty compared with routine stenting or successful balloon angioplasty in acute myocardial infarction are unknown. In the CADILLAC trial, 168 of 1,044 patients (16.1%) randomized to balloon angioplasty crossed over to stenting after unsuccessful dilatation. Event-free survival was similar after bail-out and routine stenting, and was greater than after successful balloon angioplasty.
Le texte complet de cet article est disponible en PDF.© 2003
Excerpta Medica Inc. Tous droits réservés.
Vol 92 - N° 9
P. 1095-1098 - novembre 2003 Retour au numéro
Article précédent
- Outcomes following Bail-Out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial)
- Dale T. Ashby, Eve A. Aymong, James E. Tcheng, Cindy L. Grines, David A. Cox, Roxana Mehran, Eulogio Garcia, John J. Griffin, Giulio Guagliumi, Thomas Stuckey, Mark Turco, Alexandra J. Lansky, Gregg W. Stone
- Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet–platelet and leukocyte–platelet aggregation
- Andrew L Frelinger, Mark I Furman, Marc R Barnard, Lori A Krueger, Michael W Dae, Alan D Michelson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?